Abstract
5084Background: Immune checkpoint inhibitors (ICIs) have yet to demonstrated efficacy as monotherapy in non-MSI-HI prostate cancer. Vaccines may increase immune cells in the tumor microenvironment,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
